Page last updated: 2024-10-22

anastrozole and Bone Diseases, Metabolic

anastrozole has been researched along with Bone Diseases, Metabolic in 9 studies

Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.

Research Excerpts

ExcerptRelevanceReference
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures."9.30Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019)
"6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer."9.13Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008)
"In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0."5.38Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012)
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures."5.30Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019)
"6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer."5.13Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008)
"Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels."2.44Skeletal effects of drugs to treat cancer. ( Vestergaard, P, 2008)
"In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0."1.38Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012)
"University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied."1.35Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Livi, L1
Scotti, V1
Desideri, I1
Saieva, C1
Cecchini, S1
Francolini, G1
Becherini, C1
Delli Paoli, C1
Visani, L1
Salvestrini, V1
De Feo, ML1
Nori, J1
Bernini, M1
Sanchez, L1
Orzalesi, L1
Bianchi, S1
Meattini, I1
Sestak, I1
Blake, GM1
Patel, R1
Coleman, RE1
Cuzick, J1
Eastell, R1
Vestergaard, P1
Gnant, M1
Mlineritsch, B1
Luschin-Ebengreuth, G1
Kainberger, F1
Kässmann, H1
Piswanger-Sölkner, JC1
Seifert, M1
Ploner, F1
Menzel, C1
Dubsky, P1
Fitzal, F1
Bjelic-Radisic, V1
Steger, G1
Greil, R1
Marth, C1
Kubista, E1
Samonigg, H1
Wohlmuth, P1
Mittlböck, M1
Jakesz, R1
Gibson, K1
O'Bryant, CL1
Geisler, J1
Lønning, PE1
Markopoulos, C2
Tzoracoleftherakis, E1
Koukouras, D1
Venizelos, B1
Zobolas, V1
Misitzis, J1
Xepapadakis, G1
Gogas, H1
Denes, AE1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial[NCT02616744]Phase 2171 participants (Actual)Interventional2011-01-31Completed
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646]Phase 31,803 participants (Actual)Interventional1999-06-30Completed
A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163]Phase 222 participants (Actual)Interventional2015-02-03Terminated (stopped due to The study stopped prematurely due to the low accrual rate)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for anastrozole and Bone Diseases, Metabolic

ArticleYear
Skeletal effects of drugs to treat cancer.
    Current drug safety, 2008, Volume: 3, Issue:3

    Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Meta

2008

Trials

3 trials available for anastrozole and Bone Diseases, Metabolic

ArticleYear
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 108

    Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density

2019
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
    Bone, 2019, Volume: 124

    Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac

2019
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2008

Other Studies

5 other studies available for anastrozole and Bone Diseases, Metabolic

ArticleYear
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2008, Volume: 14, Issue:3

    Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic

2008
Impact of aromatase inhibitors on bone health in breast cancer patients.
    The Journal of steroid biochemistry and molecular biology, 2010, Feb-28, Volume: 118, Issue:4-5

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones;

2010
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:4

    Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me

2010
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:9

    Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit

2012
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
    The New England journal of medicine, 2005, Nov-24, Volume: 353, Issue:21

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera

2005